Akaal Pharma is advancing a first-in-class S1P1 receptor programme — with breakthrough clinical results in both topical and oral formulations, and a superior safety profile over existing therapies.
Akaal Pharma develops novel therapies that prioritise patient safety, efficacy, and affordability — targeting inflammatory and autoimmune diseases through a highly druggable biological receptor with validated clinical potential.
We undertake early-stage drug discovery, creating best-in-class and first-in-class drug candidates for areas of significant unmet medical need.
Both Takp-119 (topical) and Oakp-11 (oral) have completed significant clinical milestones, with compelling safety and efficacy data positioning Akaal Pharma as a leader in S1P1-targeted therapeutics.
The S1P1 (sphingosine-1-phosphate receptor 1) is a highly druggable biological receptor with broad relevance across multiple disease areas. Existing S1P1 therapies carry significant limitations — Akaal Pharma's approach overcomes them all.
We are open to licensing discussions for Takp-119 and Oakp-11 — particularly with partners who have established commercial infrastructure in dermatology and autoimmune markets globally.
We welcome co-development partnerships with pharmaceutical companies and research institutions to accelerate clinical programmes and expand into new indications and geographies.
We are seeking strategic investors to support Phase 3 development of Takp-119 and Phase 2 advancement of Oakp-11 — a compelling risk-return profile backed by strong clinical data.